Menu
 

AANN 53rd ANNUAL EDUCATIONAL MEETING

Saturday, April 17-Tuesday, April 20, 2021

Connecting. Educating. Inspiring.

Virtual Industry Posters (Non-CE)

Safety and Tolerability of NRL-1, an Intranasal Formulation of Diazepam, in Relationship to Usage Frequency in Subjects with Epilepsy: Interim Results from a Phase 3, Open-Label, Repeat Dose Study

This phase 3, repeat dose, open-label study evaluated the safety of diazepam nasal spray in epilepsy subjects who, in the opinion of the investigator, may need benzodiazepine intervention for seizure control at least once every other month on average (i.e., average 6 times a year).

View the poster

Sponsored by
Neurelis Logo Combination
Please forward all questions regarding our posters to medinfo@neurelis.com.

Efficacy and Safety of Once Daily Opicapone 50 mg in Patients with Parkinson’s Disease and Motor Fluctuations: Pooled Analysis of Two Randomized, Double-Blind, Placebo-Controlled Studies

Opicapone is a once daily catechol-O-methyltransferase inhibitor under U.S. FDA review as an adjunct to levodopa/carbidopa for patients with Parkinson’s disease experiencing OFF episodes. Results from two pivotal Phase 3 trials (BIPARK-1[NCT01568073], BIPARK-2[NCT01227655]) were pooled to evaluate the efficacy and safety of opicapone 50 mg in patients with Parkinson’s disease and motor fluctuations.

View the poster

Sponsored by
Neurocrine Logo
Please forward all questions regarding our posters to medinfo@neurocrine.com.

Health-Related Quality of Life in Patients with Possible Tardive Dyskinesia Based on Patient and Clinician Assessments

Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged antipsychotic use. In this real-world screening study, patients with involuntary movements who were treated with antipsychotics were assessed. Post hoc analyses were conducted to measure the impact of possible TD on patient health-related quality of life.

View the poster

Sponsored by
Neurocrine Logo
Please forward all questions regarding our posters to medinfo@neurocrine.com.

Safety and Efficacy of Inbrija (Levodopa Inhalation Powder, CVT-301) on Motor Function During OFF Periods in Patients with Parkinson’s Disease

As Parkinson’s disease (PD) advances, patients will experience OFF periods, which are when Parkinson’s disease symptoms return despite baseline oral therapies. Inbrija® (CVT-301), an inhaled levodopa, is indicated for treatment of OFF episodes in patients with PD on a carbidopa/levodopa regimen. This poster reviews Inbrija’s effificacy and safety and povides insight into clinical experience and use.

View the poster

Sponsored by
Acorda Logo
Please forward all questions regarding our posters to medaffairs@acorda.com.